Prenosis: The Sepsis AI That Dared to Seek FDA Clearance Early

A quick editor’s note: We’ve reviewed this piece as of September 21, 2026, and all the core facts are still solid. Specifically:

• The Sepsis ImmunoScore’s FDA De Novo authorization on April 3, 2024, is confirmed history.
• It remains the first and only FDA-authorized AI/ML diagnostic for sepsis.
• Bobby Reddy Jr. is still the CEO of Prenosis.
• The regulatory discussion around Clinical Decision Support (CDS), Software as a Medical Device (SaMD), and the De Novo pathway reflects the FDA’s current guidance, which continues to evolve with updates in 2024-2026. No changes needed. AI in healthcare constantly struggles with a tension between rapid innovation and patient safety. You see this play out in the regulatory strategies companies choose. While many hunt for loopholes and exemptions, a different story is emerging, one where companies actively seek out tough, third-party validation even when it’s not technically required. This is a deep dive into Prenosis and its Sepsis ImmunoScore, offering a look at what responsible AI in health actually means for buyers, investors, clinicians, and anyone interested in regulatory literacy.
  

  The First FDA-Authorized AI Diagnostic for Sepsis

On April 3, 2024, Chicago-based Prenosis, Inc. got the first-ever FDA marketing authorization for an AI/ML diagnostic for sepsis MedTech Dive article on Prenosis FDA clearance. This sets a whole new regulatory precedent for AI in a life-or-death clinical area. The Sepsis ImmunoScore generates a risk score across four distinct risk categories within 24 hours, using an algorithm that analyzes 22 different clinical parameters. To get there, Prenosis developed and validated the tool on a massive dataset, over 100,000 blood samples from more than 25,000 patients across 10 different research sites Prenosis press release on Sepsis ImmunoScore validation. This is the kind of rigorous, data-heavy work that defines clinically validated AI and separates it from the unguarded AI solutions that lack any real empirical backing.

Proactive Regulatory Strategy: A Choice, Not a Requirement

What’s interesting about Prenosis’s move is that they chose to pursue FDA clearance before it was mandatory. As CEO Bobby Reddy Jr. put it, “we don’t think it’s right to have this out on the market without third-party validation.” That’s a direct shot at the prevailing get-to-market-fast attitude. This proactive choice is a stark contrast to how other AI sepsis tools operate, including some big names like the Epic Sepsis Model, which currently runs under a Clinical Decision Support (CDS) exemption. CDS tools are useful, but their regulatory path is much less demanding than the one for Software as a Medical Device (SaMD) that actually makes a diagnostic call. The line between a CDS giving ‘recommendations’ and a diagnostic AI making ‘determinations’ is a critical one for regulators trying to figure out how much scrutiny to apply FDA guidance on CDS vs. SaMD. Reddy’s comment points to a “culture clash” in health AI between companies that grew up in the regulated medical device world and those that didn’t. For any hospital buyer or investor, this proactive stance is a huge signal of regulatory de-risking and a commitment to a higher standard of evidence, which is what builds market acceptance.

The De Novo Pathway: Working through Novelty

Prenosis went to the FDA through the De Novo classification pathway. This route is for new, low-to-moderate-risk devices that don’t have a ‘predicate’, an existing, legally marketed device to compare against. A 510(k) clearance just requires showing you’re ‘substantially equivalent’ to something already out there, but De Novo forces you to demonstrate safety and effectiveness from the ground up because you’re the first of your kind. When you have an AI/ML diagnostic that introduces a function that’s never existed before, De Novo is really the only appropriate path. Making this choice, and shouldering the heavier review process that comes with it, shows just how serious Prenosis was about getting proper validation. Their success in getting the Sepsis ImmunoScore through this process now is a concrete playbook for other AI-native companies trying to build authority in a regulatory environment that’s changing by the month.

Validation Beyond the Algorithm: The “What Responsible AI Does Differently” Panel

The Prenosis story is a perfect example of what responsible AI development looks like in practice. For investors worried about things like algorithmic drift and data moats, the depth of Prenosis’s validation work is everything. Their model was trained and validated on over 100,000 blood samples from 25,000+ patients across ten different sites, a dataset that not only sharpens the model’s accuracy but also helps it generalize across different populations, avoiding the bias that plagues models trained on narrow data. Compare that to unguarded AI, where a model might get pushed into a clinical workflow without any of this third-party validated proof. These tools might seem fast or cheap upfront, but they carry huge risks of getting drug interactions wrong, missing a diagnosis, or undertriaging a patient having a stroke. When there’s no solid Quality Management System (QMS) or adherence to Good Machine Learning Practice (GMLP), you’re just accumulating health risks and regulatory debt. Prenosis’s work, on the other hand, follows GMLP to the letter, which is the sign of a mature, serious company.

Implications for Buyers, Investors, and Clinicians

For a buyer at a hospital system, that FDA authorization is a clear sign of reliability. Investing in a diagnostic with De Novo clearance means you have a degree of assurance about its safety and effectiveness that you just don’t get with unregulated tools. It lowers the institution’s risk in adopting the technology and makes it much easier to get buy-in from the clinicians who have to use it. Investors should also be paying attention. Proactively going after a tough regulatory clearance like De Novo is a major competitive differentiator. It shows the company has a long-term vision and understands the field, which de-risks the investment by clearing a path to reimbursement and heading off future regulatory problems. In a market littered with ‘zombie’ AI startups that couldn’t scale or find a market after their first funding round, this kind of regulatory foundation is a powerful sign of a company built to last. For clinicians on the front lines, what matters is confidence. An FDA-authorized diagnostic gives them that. The Sepsis ImmunoScore, with its transparent risk scoring and deep validation, is a tool that can actually help them make better decisions instead of just adding more noise. This is absolutely critical with something as fast-moving as sepsis, where a few hours can be the difference between life and death. How can a doctor trust a black box algorithm when a patient’s life is on the line? They can’t. The difference between a clinically validated AI and AI-powered health misinformation is that one gives clinicians reliable data, while the other erodes trust and can get people hurt. The story of Prenosis and its Sepsis ImmunoScore is a great case study in how to develop and deploy AI responsibly in healthcare. By taking on the challenge of FDA De Novo authorization, Prenosis delivered a valuable diagnostic tool and set a much higher bar for regulatory strategy in the health AI business. This focus on getting third-party validation, even when it’s not strictly required, demonstrates a real commitment to patient safety and clinical results that ought to resonate with everyone working in this space.